Skip to content
10-K

Annual Report

Terns Pharmaceuticals, Inc.

0001193125-26-131828

← back to feed
Filed
Mar 30, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 27, 2026 115.41M sh
Shares Diluted FY 2025 · Dec 31, 2025 93.17M sh
Shares Diluted FY 2025 · Dec 31, 2024 79.51M sh
Capex FY 2025 · Dec 31, 2025 $0
Capex FY 2025 · Dec 31, 2024 $42K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$82.18M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$70.02M
Cash And Equivalents FY 2025 · Dec 31, 2025 $524.75M
Cash And Equivalents FY 2025 · Dec 31, 2024 $161.44M
Stockholders Equity FY 2025 · Dec 31, 2025 $1.01B
Stockholders Equity FY 2025 · Dec 31, 2024 $345.87M
Stockholders Equity FY 2025 · Dec 31, 2023 $255.37M
Current Liabilities FY 2025 · Dec 31, 2025 $16.41M
Current Liabilities FY 2025 · Dec 31, 2024 $15.65M
Total Liabilities FY 2025 · Dec 31, 2025 $18.55M
Total Liabilities FY 2025 · Dec 31, 2024 $18.06M
Current Assets FY 2025 · Dec 31, 2025 $1.02B
Current Assets FY 2025 · Dec 31, 2024 $362.11M
Total Assets FY 2025 · Dec 31, 2025 $1.03B
Total Assets FY 2025 · Dec 31, 2024 $363.93M
Eps Diluted FY 2025 · Dec 31, 2025 −$1.03
Eps Diluted FY 2025 · Dec 31, 2024 −$1.12
Eps Basic FY 2025 · Dec 31, 2025 −$1.03
Eps Basic FY 2025 · Dec 31, 2024 −$1.12
Sga Expense FY 2025 · Dec 31, 2025 $32.24M
Sga Expense FY 2025 · Dec 31, 2024 $31.76M
Net Income FY 2025 · Dec 31, 2025 −$96.21M
Net Income FY 2025 · Dec 31, 2024 −$88.85M
Operating Income FY 2025 · Dec 31, 2025 −$110.12M
Operating Income FY 2025 · Dec 31, 2024 −$101.87M